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Objectives The aims of this study were to perform an individual patient data meta-analysis of studies using B-type natriuretic
peptides (BNPs) to predict the primary composite endpoint of cardiac death and nonfatal myocardial infarction (MI)
within 30 days of vascular surgery and to determine: 1) the cut points for a natriuretic peptide (NP) diagnostic, opti-
mal, and screening test; and 2) if pre-operative NPs improve the predictive accuracy of the revised cardiac risk index
(RCRI).
Background NPs are independent predictors of cardiovascular events in noncardiac and vascular surgery. Their addition to
clinical risk indexes may improve pre-operative risk stratification.
Methods Studies reporting the association of pre-operative NP concentrations and the primary study endpoint, post-operative major
adverse cardiovascular events (defined as cardiovascular death and nonfatal MI) in vascular surgery, were identified by elec-
tronic database search. Secondary study endpoints included all-cause mortality, cardiac death, and nonfatal MI.
Results Six data sets were obtained, 5 for BNP (n  632) and 1 for N-terminal pro-BNP (n  218). An NP level higher
than the optimal cut point was an independent predictor for the primary composite endpoint (odds ratio: 7.9;
95% confidence interval: 4.7 to 13.3). BNP cut points were 30 pg/ml for screening (95% sensitivity, 44% speci-
ficity), 116 pg/ml for optimal (highest accuracy point; 66% sensitivity, 82% specificity), and 372 pg/ml for diag-
nostic (32% sensitivity, 95% specificity). Subsequent to revised cardiac risk index stratification, reclassification
using the optimal cut point significantly improved risk prediction in all groups (net reclassification improvement
58%, p  0.000001), particularly in the intermediate-risk group (net reclassification improvement 84%, p 
0.001).
Conclusions Pre-operative NP levels can be used to independently predict cardiovascular events in the first 30 days after vas-
cular surgery and to significantly improve the predictive performance of the revised cardiac risk index. (J Am
Coll Cardiol 2011;58:522–9) © 2011 by the American College of Cardiology Foundation
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July 26, 2011:522–9 Meta-Analysis of BNP in Vascular Surgerywith the majority of these procedures being noncardiac
surgery. In a recent international randomized controlled
study (8,351 patients, 190 hospitals in 23 countries),
6.9% of patients age 45 years or older with or at risk of
cardiovascular disease who were hospitalized for noncar-
diac surgery had cardiovascular events (cardiovascular
death, nonfatal myocardial infarction [MI], nonfatal
cardiac arrest) within 30 days (2). Patients presenting for
vascular surgery have a particularly high cardiovascular
disease burden. As a result, they experience higher rates of
perioperative mortality, adverse cardiovascular events, and
rehospitalizations than patients undergoing other non-
cardiac procedures (3,4).
Pre-operative risk stratification enables both patients and
physicians to make informed decisions regarding the appro-
priateness of surgery when considering the risk for a
perioperative cardiovascular event. In addition, the identi-
fication of high-risk patients allows targeted resource allo-
cation during the perioperative period by directing addi-
tional pre-operative testing and perioperative monitoring.
Current guidelines make use of clinical risk factors,
exercise tolerance, and type of surgery to estimate peri-
operative cardiovascular risk and direct pre-operative
investigation (5). These clinical risk factors, which in-
clude a history of ischemic heart disease, compensated or
prior heart failure, cerebrovascular events, diabetes mel-
litus, and renal insufficiency, have been derived from a set
of risk factors known as the revised cardiac risk index
(RCRI) (6). To date, the use of the RCRI and the
performance of noninvasive tests and imaging studies as
directed by the guidelines have not provided good dis-
crimination when applied to patients undergoing vascular
surgery (7–9).
Ventricular cardiomyocytes secrete B-type natriuretic
peptide (BNP), a prohormone, and its inactive cleavage
product N-terminal fragment (N-terminal pro-B-type
natriuretic peptide [NT-proBNP]), into the blood in
response to atrial or ventricular wall stretch. Pre-
operative elevations of BNP or NT-proBNP have con-
sistently and independently been associated with adverse
cardiovascular events in noncardiac and particularly major
vascular surgery (10 –23). We aimed to study the fol-
lowing questions: 1) What is the optimal BNP cutoff
to predict cardiovascular events after vascular surgery?
2) Does the use of pre-operative natriuretic peptides
(NPs), BNP or NT-proBNP, improve upon current risk
stratification tools?
Methods
We aimed to perform an individual patient data meta-
analysis of studies using NPs to predict major adverse
cardiac events (MACE) and all-cause mortality within 30
days of vascular surgery. MACEs were defined as the
composite of cardiac death and nonfatal MI. In addition, we
aimed to determine the NP cutoffs for: 1) a diagnostic test; n2) a general optimal test; and 3) a
screening test (24), as well as to
determine if the pre-operative
use of NP assessment improves
the predictive performance of the
RCRI (6).
Study identification and selection.
Studies reporting on the associ-
ation of pre-operative NP con-
centrations and post-operative
cardiovascular events in adults
undergoing noncardiac vascular
surgery were identified by elec-
tronic searches of the MEDLINE
(July 5, 2010) and EMBASE
(week 26 of 2010) databases. The
electronic searches were completed
by manual search of the reports’
reference lists. The terms used in
the search strategy were “natri-
uretic peptides,” “surgery or sur-
gical procedures,” and validated
combinations of prognostic
terms (25) and diagnostic terms (26,27). No language
restriction was applied.
Congress abstracts, studies in cardiac surgery populations,
and studies in which BNP administration was part of an
interventional algorithm were excluded. To avoid the inclu-
sion of duplicate study data from reports publishing partial
results, the study with the most complete follow-up or
largest sample size was included. Study quality issues in the
study selection process were not considered. Working as 2
groups (C.S.B. and G.A.L.B., R.N.R. and G.A.L.B.), we
independently selected studies according to predefined eli-
gibility criteria. Selections inconsistencies were resolved by
consensus.
Data collection. The investigators of eligible studies were
contacted by e-mail a maximum of 3 times to obtain
individual patient data for pre-operative BNP or NT-
proBNP concentrations and the type of noncardiac surgery
conducted, history of coronary artery disease, congestive
cardiac failure, cerebrovascular disease, diabetes mellitus,
and renal failure (creatinine 2 mg/dl) to obtain the
individual RCRI for each patient. Information on all pa-
tients who had undergone vascular surgery was extracted
from the individual databases as supplied by the investiga-
tors of each study and subsequently merged. After merging,
a random sample of 20% of the cases were checked for
accuracy against the original data sets provided by the
investigators, and no errors were detected (kappa  1).
tudy quality assessment. All studies included for meth-
dological and reporting quality were evaluated according to
he Quality Assessment of Diagnostic Accuracy Studies
hecklist (28), adapting the checklist for the purposes of this
eview because all the included studies were prognostic in
Abbreviations
and Acronyms
AUC  area under the
receiver-operating
characteristic curve
BNP  B-type natriuretic
peptide
CI  confidence interval
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
NP  natriuretic peptide
NRI  net reclassification
improvement
NT-proBNP  N-terminal
pro-B-type natriuretic
peptide
OR  odds ratio
RCRI  revised cardiac
risk index
ROC  receiver-operating
characteristicature (Online Appendix). In the adapted checklist’s for-
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standard” were replaced by “natriuretic peptide concentra-
tions,” “all-cause mortality,” and “outcome,” respectively.
Criteria 3, 4, 7, and 13 of the original checklist (28) were
regarded as not applicable in this context. Criterion 9
(execution of outcome assessment) of the original checklist
was considered as not applicable for the studies addressing
in-hospital all-cause mortality only. Two authors (G.A.L.B.
and C.S.B.) independently rated study quality.
Figure 1 Flow Chart of Included and Excluded Studies
Flow chart demonstrating the results of a structured electronic database search o
pre-operative natriuretic peptide (NP) concentration and post-operative cardiovascu
search strategy were “natriuretic peptides,” “surgery or surgical procedures,” and
Characteristics of Studies Identified as Including Vascular SurgeryTable 1 Characteristics of Studies Identified as Including Vasc
First Author, Year (Ref. #)
Proportion Vascular
Surgery (%)
Male
(%)
Yeh et al., 2005 (31) 6/190 (3) 50
Cuthbertson et al., 2007 (30) 61/204 (30) 61
Feringa et al., 2007 (15) 335 (100) 76
Gibson et al., 2007 (16) 88/190 (59) 65
Mahla et al., 2007 (20) 218 (100) 78
Leibowitz et al., 2008 (19) 3/44 (7) 41
Riemersma et al., 2008 (32) 19 (100) 68
Bolliger et al., 2009 (10) 133 (100) 85
Choi et al., 2009 (12) 534/2,054 (26) 61
Goei et al., 2009 (17) 592 (100) 76
Biccard et al., 2011 (33) 297 (100) 64*Thresholds reflect the optimal general cut point as defined in each individual study.
NP  natriuretic peptide.Statistical analysis. Frequencies are described as numbers
and/or percents. Age is described as a mean and agreement
between the authors for eligibility of the retrieved studies as
a kappa value.
Before merging study data, the association between BNP
concentration and MACE heterogeneity across studies was
assessed using chi-square analysis, and a meta-analysis was
conducted using Review Manager version 4.3 for Windows
(The Cochrane Collaboration, Copenhagen, Denmark).
INE and EMBASE conducted to identify studies reporting on the association of
nts in adults undergoing noncardiac vascular surgery. The terms used in the
ted combinations of prognostic and diagnostic terms.
surgery Cases
Mean Age
(yrs)
Patients With NP Levels
Above Thresholds* (%)
Individual Patient
Data Available
57 Not reported No
66 38 Yes
62 35 No
68 21 Yes
70 Not reported Yes
77 41 Yes
69 89 No
68 57 Yes
68 27 Yes
70 35 No
59 44 Yesf MEDL
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July 26, 2011:522–9 Meta-Analysis of BNP in Vascular SurgeryRandom-effects or fixed-effects models were used according
to the presence or absence of significant heterogeneity
between studies, respectively.
The association between NP concentration and MACEs
at 30 days was determined using backward stepwise logistic
regression, and pooled dichotomous outcomes are reported
as odds ratios (ORs) with 95% confidence intervals (CIs).
Statistical analysis was performed using SPSS version 15.0
for Windows (SPSS, Inc., Chicago, Illinois).
The general optimal test cutoff value, also known as the
optimal diagnostic point, is the point that optimizes the rate
of true-positive results while minimizing the rate of false-
positive results, thereby reflecting the point with the highest
accuracy for the prediction of study endpoints. For both
NT-proBNP and BNP, this was defined by receiver-
operating characteristic (ROC) statistics using a 1:1 weight-
ing of sensitivity and specificity and the point determined by
the value with the minimal distance when using the formula
distance  (1  sensitivity)2  (1  specificity)2 (24). The
screening cutoff point was chosen at a sensitivity of 95%
while optimizing specificity. Similarly, the diagnostic cutoff
point was chosen at a specificity of 95% while optimizing
sensitivity (24).
Patient Characteristics of Merged DatasetsTable 3 Patient Characteristics of Merged D
Variable
All Patients
(n  850)
M
Age (yrs) 65.3 12.1
Men 561 (66%)
Type of surgery
Vascular, infrainguinal 629 (74%)
Vascular, aortoiliac 217 (25.5%)
Vascular, not specified 4 (0.5%)
RCRI class
Low (RCRI 0) 320 (37.6%)
Intermediate (RCRI 1 or 2) 476 (56%)
High (RCRI 3) 54 (6.4%)
RCRI components
Coronary artery disease 327 (38.5%)
Congestive heart failure 64 (7.5%)
Cerebrovascular disease 145 (17.1%)
Diabetes mellitus 204 (24%)
Creatinine 2 mg/dl 28 (3.3%)
Characteristics of the Vascular Studies From Which Data Were ReTable 2 Characteristics of the Vascular Studies From hich Da
First Author, Year (Ref. #) Patients Contributed Biomarker
Mahla et al., 2007 (20) 218 NT-proBNP
Cuthbertson et al., 2007 (30) 70 BNP
Gibson et al., 2007 (16) 129 BNP
Leibowitz et al., 2008 (19) 3 BNP
Bolliger et al., 2009 (10) 133 BNP
Biccard et al., 2011 (33) 297 BNP
BNP  B-type natriuretic peptide; NT-proBNP  N-terminal pro-B-type natriuretic peptide.Values are mean  SD or as n (%).
MACE  major adverse cardiac event(s); RCRI  revised cardiac risk indexPatients were categorized according to their RCRI risk
groups (0  low risk; 1 or 2  intermediate risk; 3, 4, or
5  high risk) and then reclassified according to their
re-operative NP concentrations (above or below the gen-
ral optimal test cutoff) (29). The reclassification by net
eclassification improvement (NRI) was then tested for
iscrimination and reclassification calibration statistics.
Two-sided p values were used in all analyses, and
alues 0.05 were considered significant.
EpiCalc 2000 version 1.02 (Brixton Books, London,
.K.), SAS version 9.1 (SAS Institute Inc., Cary, North
arolina) and Excel 2007 (Microsoft Corporation, Red-
ond, Washington) were used for statistical analysis.
esults
tudy identification and selection. The literature search
etrieved 1,648 citations, of which 15 noncardiac surgery
tudies fulfilled the eligibility criteria (Fig. 1). The kappa
alue for eligibility was 0.809.
Of these 15 studies, 10 were identified as containing
ascular surgery patients (10,12,15–17,19,20,30–32) (Table 1).
ndividual datasets were obtained from 6 studies, 5 datasets
eporting BNP values in 632 vascular patients (10,13,16,19,30)
ets
at 30 Days
 75)
No MACE at 30 Days
(n  775) p Value
4 8.8 65.0 12.3 0.003
(65.3%) 512 (66.1%) 1.00
(66.7%) 579 (74.7%) 0.572
(33.3%) 192 (24.8%) 0.24
0 4 (0.5%) 1.00
(25.3%) 301 (38.8%) 0.117
(60%) 431 (55.6%) 0.691
(14.7%) 43 (5.5%) 0.01
(56%) 285 (36.8%) 0.05
(18.7%) 50 (6.5%) 0.003
(10.7%) 137 (17.7%) 0.254
(33.3%) 179 (23.1%) 0.143
(8%) 22 (2.8%) 0.037
dere Received
Diagnostic Assay Cutoff (pg/ml)
lecsys (Roche Diagnostics, Mannheim, Germany) 280
DVIA Centaur (Bayer Diagnostics, Leverkusen, Germany) 35
hinoria BNP kit, Shionogi & Company, Ltd., Osaka, Japan) 108.5
DVIA Centaur 165
xSYM BNP (Abbott Laboratories, Abbott Park, IL) 50
DVIA Centaur Xp 39atas
ACE
(n
69.
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50
25
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42
14
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Meta-Analysis of BNP in Vascular Surgery July 26, 2011:522–9and 1 study measuring NT-proBNP concentrations in 218
vascular patients (20), for a total dataset of 850 patients having
undergone both open and catheter-based vascular surgery. A
study that has recently been accepted for publication and
fulfilled the criteria was also included (33). The characteristics
of the studies for which data were received are shown in
Table 2. On analysis, the included studies showed signifi-
cant heterogeneity (chi-square  13.37, I2  70.1%) in the
unadjusted association between BNP and 30-day MACEs.
The characteristics for the merged patient population are
shown in Table 3.
Study quality. All of the 11 included studies fulfilled the
requirements of a representative spectrum of patients by
having clearly defined inclusion and exclusion criteria,
outcome verification of the whole cohort, equal outcome
evaluation regardless of the NP results, sufficient descrip-
tion of NP measurement, and availability of clinical data.
We considered the description of the NP measurement
(index test) sufficient for replication in 9 of the studies
(10,15–17,19,20,30,31,33). Of the 6 studies (10,15,16,20,30,32)
that monitored for MACEs after discharge, 3 provided
detailed descriptions of their follow-up methods (10,20,30).
In only 2 studies were the NP results interpreted without
knowledge of outcome (15,16), and only 5 stated that
outcomes were determined without knowledge of the NP
results (10,16,20,30,31). Two of the 7 studies that lost
patients from follow-up provided reasons for this loss or
withdrawal (30,34).
Predictive value of NPs. Figure 2 indicates the results of
he meta-analysis of the individual studies in predicting
Figure 2 Unadjusted ORs for a Pre-Operative BNP or NT-proBNP
(BNP 116 pg/ml, NT-proBNP 277.5 pg/ml) in Predi
Forest plot showing the individual and pooled unadjusted odds ratios (ORs) from t
BNP  B-type natriuretic peptide; CI  confidence interval; NT-proBNP  N-terminaACEs before the merging of the datasets using a random-ffects model. The 3 patients from the study by Leibowitz et
l. (19) were not included in the analysis, because they
rovided only true-positive results.
Using the merged dataset, the general optimal test cut
oints for the BNP (116 pg/ml) and NT-proBNP (277.5
g/ml) groups were determined as described in our “Meth-
ds” section. Patients were then classified as falling above or
elow this point.
The following independent predictors of MACEs were
dentified by backward stepwise logistical regression analy-
is: NP level higher than the optimal cut point (OR: 7.9;
5% CI: 4.7 to 13.3), aortoiliac surgery (OR: 2.1; 95% CI:
.2 to 3.6), and diabetes mellitus (OR: 1.9; 95% CI: 1.1 to
.3). The ORs for NP higher than the threshold were 4.3
95% CI: 1.7 to 11.3) for cardiac death, 7.5 (95% CI: 4.1 to
3.6) for nonfatal MI, and 3.1 (95% CI: 1.4 to 6.7) for
ll-cause mortality within 30 days of vascular surgery.
Because only 1 NT-proBNP dataset was available, a ROC
nalysis for pre-operative BNP and the RCRI (n  632) in
AUCs for BNP and the RCRI inPredicting Perioperative Outcomes (n  632)Table 4 AUCs for BNP and the RCRI inPredicting Perioperative Outcomes (n  632)
BNP RCRI
Outcome AUC (%) 95% CI (%) AUC (%) 95% CI (%)
MACEs 80.5 75.1–85.8 64.5 56.6–72.3
Cardiac death 80.0 71.5–88.6 67.1 53.8–80.5
Nonfatal MI 78.6 72.2–85.5 62.3 52.8–71.7
All-cause mortality 71.4 60.7–82.2 63.8 53.2–74.3
centration Above the Optimal General Cut Point
Cardiovascular Outcomes 30 Days After Surgery
luded studies.
-type natriuretic peptide.Con
cting
he inc
l pro-BAUC  area under the receiver-operating characteristic curve; BNP  B-type natriuretic peptide;
CI  confidence interval; MI myocardial infarction; other abbreviations as in Table 3.
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July 26, 2011:522–9 Meta-Analysis of BNP in Vascular Surgerypredicting perioperative events was performed on the BNP
dataset alone (Table 4).
Determination of BNP screening and diagnostic cutoff
points. Because there was only a single study in the
NT-proBNP group, we calculated screening and diagnostic
cut points for the BNP group only (n  632). Having
determined the optimal general cutoff point for BNP to be
116 pg/ml, the BNP level for a screening test with 95%
sensitivity was determined to be 30 pg/ml, and a BNP level
of 372 pg/ml was determined for a diagnostic test with 95%
specificity. Table 5 shows the test characteristics at these 3
cutoff concentrations in predicting MACE at 30 days.
The area under the ROC curve (AUC) for BNP as a
continuum in predicting MACE was 80.5% (95% CI:
75.1% to 85.8%). A reduced ROC curve using only these 3
cutoff points resulted in an AUC of 80.1% (95% CI: 74.3%
to 80%). The incidence of MACE stratified according to
these 3 cut points is shown in Table 6.
RCRI reclassification. Per the American College of Car-
diology and American Heart Association guidelines on
perioperative cardiovascular evaluation and care for noncar-
diac surgery (5), all 850 patients were classified into 3 risk
groups according to their RCRI scores. A reclassification
was performed on the basis of the patients’ NP levels. If
levels fell below the optimal general cut point, patients were
moved down 1 risk category, and if levels fell above the
optimal general cut point, patients were moved up 1 risk
category (29).
Table 7 shows the results of the reclassification process.
In patients classified as low risk by the RCRI, 20% were
reclassified as intermediate by the use of NP concentration.
In patients classified as intermediate risk by the RCRI, 71%
were reclassified as low risk and 28.5% as high risk. In those
classified as high risk by the RCRI, 54% were reclassified as
intermediate risk. Overall, the use of NP resulted in a
statistically significant improvement in discrimination, with
Test Characteristics at 3 BNP Cutoff Pointsin Predicting 30-Day MACEsTable 5 Test Characteristics at 3 BNP Cutoff Pointsin Predicting 30-Day MACEs
Cutoff Point
BNP
(pg/ml)
Sensitivity
(%)
Specificity
(%) LR LR
Screening 30 95 44 1.69 0.11
General optimal 116 66 82 3.6 0.41
Diagnostic 372 32 95 6.4 0.71
BNP  B-type natriuretic peptide; LR  likelihood ratio; MACE  major adverse cardiac event.
Incidence of Adverse Cardiac Events Stratified Athe Scre ning, G neral Optimal, a d DiagnosticTable 6 Incidence of Advers Cardi c Eventthe Screening, General Optimal, an
NP Threshold (pg/ml)
Below screening (0–29)
Between screening and general optimal diagnostic (30–115
Between general optimal and diagnostic (116–370)
Above diagnostic (372)Abbreviations as in Tables 1, 3, and 4.an NRI of 58% (z  5.48, p  0.001). In patients classified
s intermediate risk by the RCRI, the NRI was 84% (z 
.37, p  0.001). Applying this cutoff point to the entire
opulation, without predefining risk categories, results in a
continuous” NRI. This can be used to compare the
redictive performance of BNP with other pre-operative
isk predictors that may be identified in the future. The
ontinuous NRI was 96.4% (z  6.89, p  0.000001).
iscussion
redictive value of NP. This meta-analysis shows that
mong patients undergoing vascular surgery, elevated NPs
ere independently predictive of MACEs at 30 days in
atients undergoing vascular surgery and that the addition
f BNP to the widely used RCRI risk stratification system
ignificantly improves risk discrimination in a large propor-
ion of these patients.
This finding supports previous evidence of the indepen-
ent significant association between pre-operative BNP
oncentrations and the occurrence of cardiovascular events
fter vascular surgery (18). The validity of this association
etween NP and MACEs was supported by evidence of a
iological gradient, with increasing concentrations of NP
eing associated with an increase in the risk for MACEs.
As an individual patient data meta-analysis, this study
nabled us to determine cutoff values for pre-operative
NP, thereby overcoming the limitations of previous meta-
nalyses (18,22,23). Previous studies have focused on the
dentification of a single optimal discrimination cut point
ith which to direct patient management. Although this
ingle value is appealing, it may be more logical to make use
f a categorical classification system. When used as a
ontinuous variable to predict MACEs, BNP has an AUC
f 80.5% which falls to 74.1% when the single optimal
utoff point is used.
We propose that a categorical classification system based
n BNP cutoff points reflecting the clinical goals of screen-
ng and general optimal and diagnostic testing (24) be
nvestigated for use in pre-operative risk stratification. The
se of a categorical system would allow the maximization of
ensitivity within the lower risk groups while maximizing
pecificity in the higher risk groups (35), while maintaining
high degree of diagnostic accuracy. Future studies should
ot focus on the identification of a single cutoff point alone.
ding toValues (n  632)atified According to
gnostic BNP Values (n  632)
MACEs
(%)
Cardiac
Death (%)
Nonfatal
MI (%) OR (95% CI)
1.2 0 1.2 —
6.5 2.8 3.6 5.6 (1.6–19.6)
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d Dia
)
h
T
t
d
3
w
p
c
C
P
M
4
C
T
s
i
r
i
i
s
s
528 Rodseth et al. JACC Vol. 58, No. 5, 2011
Meta-Analysis of BNP in Vascular Surgery July 26, 2011:522–9Further work to define these cutoff points for NT-proBNP
is required.
Risk stratification in vascular surgery. Previously, the
RCRI has shown only modest performance in predicting
perioperative cardiac events in vascular surgery (36). Simi-
larly, this study has shown similar performance of the RCRI
in predicting both MACEs (AUC: 61.6%; 95% CI: 54.6%
to 68.6%) and all-cause mortality (AUC: 65.8%; 95% CI:
55.7% to 75.9%) in patients undergoing vascular surgery.
This is probably due to the RCRI’s having been derived
from a population of predominantly noncardiac nonvascular
surgery patients. In fact, in the original study in which the
RCRI was derived, the index did not perform well in
patients undergoing abdominal aortic aneurysm surgery
(AUC: 54.3  9.2%) (6).
The addition of pre-operative NP concentration to the
RCRI risk stratification resulted in the correct reclassifica-
tion of 58% of patients. A correct reclassification occurs
when a patient who had an event moves up into a higher risk
category once restratified with NP concentration, or a
patient who did not have an event is moved down a risk
category. These results suggest that in patients risk stratified
with the RCRI, the optimal BNP cutoff point should be
used to reclassify patients, thereby obtaining a more accurate
risk assessment. This would improve not only risk assess-
ment accuracy but also the identification of high-risk
patients who may benefit from further noninvasive testing.
Further work should be undertaken to determine whether
the RCRI improves pre-operative risk stratification in
patients primarily risk stratified using NPs and to examine
the role of the individual RCRI factors together with NPs in
improving pre-operative risk stratification. The findings of
this meta-analysis, together with the other studies in this
area (36), raise concerns regarding the use of the RCRI in
isolation in vascular surgery populations as proposed by the
American College of Cardiology and American Heart
Association algorithm.
Study limitations. First, individual patient data could not
be obtained for all studies that the search strategy retrieved.
In particular, the available datasets that measured NT-
proBNP were under-represented; as such, we chose to limit
the calculation of screening and diagnostic cutoff points to
the BNP dataset only. Second, 3 different BNP assay
methods were used in the studies included in this analysis
(Table 2), with a lack of standardization between assays.
The degree of imprecision is 3.5% to 4.4% for the ADVIA
system (Bayer Diagnostics, Leverkusen, Germany), 5.5% for
Change in Risk Stratification and its Relationship to Frequency ofTable 7 Change in Risk Stratification and its Relationship to F
RCRI Risk Category MACE No MACE Total
Low risk 19 (5.9%) 301 (94.1%) 320
Intermediate risk 45 (9.5%) 431 (90.5%) 476
High risk 11 (20.4%) 43 (79.6%) 54
Abbreviations as in Tables 1 and 3.the AxSYM system (Abbott Laboratories, Abbott Park,Illinois), and 8% for the Shionogi system (Shionogi &
Company, Ltd., Osaka, Japan) (37–39) The ADVIA and
Shionogi systems recognize similar BNP epitopes that differ
from those identified by the AxSYM system. As a result,
when compared with the AxSYM system, the ADVIA
system on average results in lower BNP values (38). How-
ever, all 3 BNP assays make use of a cut point of 100 pg/ml
(39), and the degree of imprecision around this shared cut
point is consistently acceptable (37–39).
Third, the I2 statistic of 70.1% indicates significant
eterogeneity in the unadjusted OR between the studies.
he incidence of MACEs is significantly different between
he NP study groups but correlated with the degree of
isease burden, as indicated by those patients with scores of
or more on the RCRI (Pearson’s correlation p  0.01). It
ould seem that as the event rate within the surgical
opulation increases, so does the predictive value of NP
oncentration.
onclusions
re-operative NP levels are able to independently predict
ACEs (OR: 7.9; 95% CI: 4.7 to 13.3), cardiac death (OR:
.3; 95% CI: 1.7 to 11.3), and nonfatal MI (OR: 7.5; 95%
I: 4.1 to 13.6) in the first 30 days after vascular surgery.
he cutoff points for pre-operative BNP when used as a
creening, optimal general, and diagnostic test for MACEs
n a vascular surgical population are 30, 116, and 372 pg/ml,
espectively. Pre-operative NP levels are able to significantly
mprove on the predictive performance of the RCRI; their
nclusion in existing pre-operative evaluation algorithms
hould be considered, and the role of the RCRI in vascular
urgery should be reviewed.
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APPENDIX
For a description of study quality assessment,
please see the online version of this article.
